- Published at
- by manilatimes.net
positive
positive
News for Pharming Group N.V. (PHAR)
- Published at
- by manilatimes.net
neutralneutral- Published at
- by manilatimes.net
mixedmixed- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by seekingalpha.com
neutralneutralPharming Group offers to buy Sweden's Abliva for SEK 0.45/shr (NASDAQ:PHAR)
Pharming Group N.V. offers a recommended public cash offer to acquire Abliva AB, valued at $66.1 million, with acceptance from major shareholders.- Published at
- by manilatimes.net
mixedmixed- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
mixedmixed- Published at
- by globenewswire.com
mixedmixedPharming Group reports third quarter 2024 financial results and provides business update
Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST® and Joenja®...- Published at
- by investing.com
positivepositivePharming buy rating and stock target continued on new trial start By Investing.com
Pharming buy rating and stock target continued on new trial start- Published at
- by globenewswire.com
neutralneutralPharming Group to report third quarter 2024 financial results on October 24
Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its...- Published at
- by globenewswire.com
positivepositivePharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to...- Published at
- by globenewswire.com
positivepositivePharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta...- Published at
- by globenewswire.com
positivepositivePharming Group to participate in September investor conferences
Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management...- Published at
- by globenewswire.com
mixedmixedPharming Group reports second quarter and first half 2024 financial results and provides business update
Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue...- Published at
- by benzinga.com
mixedmixedWhy Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Merck & Co (NYSE:MRK)
Shares of Merck & Co., Inc. MRK fell sharply during Tuesday's session after the company reported second-quarter financial results and cut its FY24 adjusted EPS ...VBIVTWOUSFMRGENPHGUFPHARM.ASPHARNVAX.MXNVAXNEO.MXNEOLUMN.MXLUMNINVOGUI.DEENVBDGED.LDGEAFDGE.PADGE.LDEOCVLTCNSPCLDXAMKR0LHP.L0HVP.L0A3S.LVRNSTLRYSWK.MXSWKPYPL34.SAPYPL.MXPYPL.BAPYPLPRG.DEPG.MXPGMRHBPMBINPMBINOMBINNMBINJBLU.MXJBLUJAW.DEHWM.BAHWM-PHWMG1AR34.SAEKSOCRWD.MXCRWDBKDKP48Z.DE2PP.DE0VOU.L0TCU.L0L9E.L0JOT.L0J38.L0ITV.L0IFR.L0A3N.LWWDTRNSRMBSRMB.DEPCSAONEWMRKD.BAMRK.SNMRK.PAMRK.MXMRKLSCCGLW.MXGLW.DEGLW.BAGLWG1LW34.SAECL.MX6MK.DE0R2X.L0QYL.L0IFA.L- Published at
- by globenewswire.com
mixedmixedPharming Group reports first quarter 2024 financial results and provides business update
First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and...